Blood–Brain Barrier Transport Platform: Humanized in vivo systems for evaluating receptor-mediated CNS delivery strategies
As part of Taconic’s Neurobiology portfolio—spanning Alzheimer’s disease, blood–brain barrier (BBB) biology, and neuroinflammation—our BBB Transport Platform supports translational evaluation of CNS delivery strategies.
Evaluate receptor-mediated CNS delivery in physiologically and disease-relevant in vivo systems designed to support transport biology, brain exposure assessment, biodistribution profiling, and translational PK/PD evaluation across established and emerging RMT pathways.
Receptor-mediated transport (RMT) strategies are increasingly being engineered to enhance central nervous system exposure across biologics, gene therapies, enzyme fusions, and other advanced therapeutic modalities. While in vitro systems are critical for early mechanistic screening and affinity characterization, translational evaluation of BBB shuttle biology often requires integrated in vivo systems capable of contextualizing receptor function within whole-organism physiology.
Brain exposure is influenced not only by receptor binding, but also by receptor density, endothelial polarity, intracellular trafficking, vascular architecture, systemic pharmacokinetics, and disease-associated changes to BBB integrity. In vivo systems may additionally support evaluation of regional biodistribution, delayed brain PK profiles, efficacy-relevant endpoints, and receptor-associated systemic biology that cannot be fully resolved in simplified cell-based systems. While commonly applied in neurobiology, receptor-mediated transport strategies may also be relevant across additional therapeutic areas.
Taconic’s Blood–Brain Barrier Transport Platform includes humanized receptor-mediated transport (RMT) shuttles designed to support translational evaluation of CNS delivery strategies under physiologically relevant in vivo conditions.
These systems target key BBB transport receptors, including Transferrin Receptor 1 (TfR1; encoded by TFRC) and the CD98 heavy chain (CD98hc; encoded by SLC3A2), which are actively leveraged for CNS delivery across biologics and other advanced therapeutic modalities.
These systems are designed to support comparative evaluation of shuttling pathways, affinity and valency optimization, translational PK/PD studies, efficacy-associated readouts, and biodistribution assessment across multiple CNS delivery architectures.
The humanized TfR1, CD98hc and CD98hc × TfR1 models enable researchers to deconvolute RMT pathway biology, optimize affinity and transport kinetics, evaluate efficacy readouts, and make more informed translational platform decisions by offering human-specific receptor expression, controlled genetic backgrounds for head-to-head pathway comparison, and in vivo systems designed to approximate clinically relevant PK/PD behavior.
The standalone CD98hc model supports focused evaluation of CD98hc-mediated transport and sustained brain exposure dynamics.
The Tfr1 model supports evaluation of TfR1-engineered central nervous system therapeutics and enables blood-brain barrier transcytosis without clinical signs of anemia.
The dual CD98hc × TfR1 cross enables comparative assessment of distinct RMT pathways within the same physiological and genetic context.
Transport behavior at the blood–brain barrier may change substantially in the context of neurodegeneration, neuroinflammation, vascular dysfunction, aging, and other CNS disease states. Evaluating receptor-mediated delivery strategies within disease-relevant biological systems may therefore be critical for understanding translational exposure dynamics and therapeutic response.
Taconic’s BBB Transport Platform is designed to support integration of humanized RMT systems with neurobiology and neurodegeneration models to contextualize transport biology within physiologically and pathologically relevant brain environments.
As receptor-mediated transport biology continues to evolve, researchers may require flexible genetic engineering and colony management strategies to support emerging transport targets, novel modality architectures, and comparative pathway studies.
Beyond model access, Taconic’s custom model generation and colony management infrastructure enables long-term, comparative BBB transport programs through controlled breeding, cohort planning, cross-generation, and study-ready execution.
Taconic’s integrated custom model generation and colony management capabilities are designed to support:
Successful evaluation of receptor-mediated CNS delivery strategies may require understanding receptor expression, tissue distribution, and pharmacokinetic context beyond simple brain uptake measurements. Taconic’s integrated model-centric capabilities are designed to support translational in vivo studies through genetic validation, study-ready cohorts, and consultative scientific planning.
Because many RMT targets are expressed beyond the brain vasculature, translational evaluation may require characterization of systemic exposure, peripheral target engagement, and tissue-specific biodistribution alongside CNS delivery.
Receptor-mediated transport (RMT) is a physiological mechanism by which endogenous receptors expressed on brain endothelial cells facilitate selective uptake and transcytosis of circulating ligands across the blood– brain barrier (BBB). Therapeutic strategies designed to leverage RMT typically involve targeting receptors that naturally undergo endocytosis and intracellular trafficking, enabling macromolecules to traverse the endothelial barrier. RMT pathways are actively explored for CNS delivery because they offer a biologically relevant alternative to passive diffusion, which is highly restricted at the BBB, particularly for large or complex therapeutic modalities.
In vivo evaluation is critical for BBB transport studies because receptor function, intracellular trafficking, and transport kinetics are influenced by whole-organism physiology that cannot be fully recapitulated in isolated in vitro systems. Factors such as receptor density, endothelial polarity, vascular architecture, systemic pharmacokinetics, and disease-associated changes to the BBB can substantially affect brain exposure and biodistribution. In vivo systems enable integrated assessment of these variables, supporting interpretation of CNS delivery behavior within a physiologically relevant context and across both brain and peripheral tissues.
While receptor binding affinity is important, brain exposure is shaped by multiple additional factors, including receptor expression levels, endothelial trafficking pathways, intracellular sorting, receptor recycling, vascular architecture, and systemic pharmacokinetics. Peripheral tissue expression of the targeted receptor and downstream biodistribution can also influence exposure profiles. In disease settings, alterations in BBB integrity, inflammation, and vascular function may further affect transport behavior. Evaluating BBB transport therefore requires systems capable of integrating receptor biology with pharmacokinetic and tissue-level context.
Transferrin Receptor 1 (TfR1) is a transmembrane protein involved in cellular iron uptake and is expressed on brain endothelial cells at the blood–brain barrier. Because TfR1 undergoes receptor-mediated endocytosis, it has been widely explored as a target for CNS delivery strategies designed to leverage RMT. TfR1-based approaches are commonly studied across advanced therapeutic modalities to support evaluation of brain exposure, biodistribution, and translational delivery concepts under physiologically relevant conditions.
CD98hc-mediated transport and TfR1-mediated transport represent distinct RMT pathways with differing receptor biology, expression patterns, and intracellular trafficking characteristics. These differences may influence transport kinetics, brain exposure profiles, and peripheral biodistribution. As a result, CD98hc has emerged as an additional pathway of interest alongside TfR1 for CNS delivery research. Comparative evaluation of these pathways in vivo can support informed selection of transport strategies aligned with specific program goals and modality architectures.
Comparing multiple RMT pathways allows researchers to evaluate how differences in receptor biology, trafficking behavior, and systemic expression influence CNS delivery performance. Because no single RMT pathway is universally optimal across all therapeutic modalities, in vivo comparison can inform decisions related to affinity tuning, valency design, dosing strategies, and translational risk. Dual-pathway and pathway-comparison systems enable head-to-head evaluation within a controlled physiological and genetic context, supporting more informed program-level decisions.
Disease states such as neurodegeneration, neuroinflammation, vascular dysfunction, and aging may alter BBB integrity, receptor expression, and intracellular transport processes. These changes can influence brain penetration, regional biodistribution, and exposure dynamics of receptor-mediated delivery strategies. Evaluating BBB transport within disease-relevant in vivo models may therefore provide additional insight into translational behavior and therapeutic response that is not fully captured in healthy systems alone.
Humanized BBB transport models are in vivo systems in which key transport receptors have been genetically engineered to express their human counterparts under endogenous regulatory control. These models are designed to support evaluation of human-specific receptor interactions, transport biology, and translational pharmacokinetics. By enabling assessment of CNS delivery strategies in a physiologically relevant context, humanized models can help reduce uncertainty associated with species differences and support more informed translational decision-making during CNS drug development.
Yes. Taconic supports cross‑breeding of customer‑owned or externally developed models with our humanized TfR1 and CD98hc lines to enable evaluation of CNS delivery strategies within your specific disease or biological context.
When cross‑breeding is performed at Taconic as part of a Colony Management Solutions program, Taconic waives all license fees associated with the use of our humanized models, simplifying project execution and reducing administrative burden.
In addition to model access, Taconic provides scientific consultation, breeding strategy design, and colony management support to help ensure successful integration of RMT biology into your program.
Email: info@taconic.com
Phone: +1 (518) 697-3900
273 Hover Ave., Germantown, NY 12526
Email: info@taconic.com
Phone:
+1 (518) 697-3915
Toll-free:
+1 (888) 822-6642
Hours:
(Monday - Friday): 7 a.m. - 6 p.m. ET
Email: info@taconic.com
Phone (Europe and Denmark):
+45 70 23 04 05
Phone (Germany):
+49 214 50 68 023
Hours: (Monday - Friday):
7 a.m. - 5 p.m. CET
